Trademark Filing in Basel.

Trademark filing Basel companies depend on begins with a hard truth for a region built on pharmaceuticals and chemicals: Switzerland sits outside the European Union, so an EU trade mark (EUTM) does not protect a brand on Swiss soil. A Roche or Novartis neighbour on the Rhine, a biotech spin-off near the Basel life-sciences campus, or a specialty-chemicals house must secure its name through the Swiss system itself — a national Swiss trade mark filed at the Swiss Federal Institute of Intellectual Property (IPI) in Bern, or a Madrid Protocol registration that designates Switzerland. PerspireIP prepares, files and manages both routes for Basel brand owners, and coordinates the pharma-specific naming checks that a Basel drug brand cannot ignore.

Why Basel’s pharma brands need a Swiss mark, not just a EUTM

The single most costly assumption a Basel company can make is that a EUTM protects the brand at home. It does not. Switzerland belongs to neither the European Union nor the European Economic Area, so a EUTM granted by the EUIPO in Alicante has no legal effect on Swiss territory. For a Basel business this is doubly dangerous, because the same EUTM does cover neighbouring France and Germany — the very markets a Basel firm ships to across the Rhine — which lulls owners into thinking the whole region is safe. It is not: the Swiss home market where the headquarters and laboratories sit remains unprotected.

There is no trade mark equivalent of the European Patent Convention that reaches into Switzerland. The Swiss market has to be claimed directly, under Swiss law, at the Swiss office. A competitor could register your exact pharmaceutical or chemical brand in Switzerland the day after your EUTM issues, and you would hold no Swiss right to stop them. For a Basel brand whose value can run into the billions, that gap is simply unacceptable.

A single Swiss national trade mark carries a quiet bonus: it automatically extends to and is enforceable in Liechtenstein under the long-standing Swiss–Liechtenstein treaties, so one filing covers two jurisdictions. The reverse never holds — a EUTM reaches Liechtenstein but never Switzerland. This is exactly why trademark filing Basel strategy is planned as its own Swiss track rather than an afterthought bolted onto an EU application.

• A EUTM covers France and Germany but stops dead at the Swiss border
• Your Basel headquarters and labs sit in the one market a EUTM cannot defend
• Switzerland must be claimed through a Swiss national mark or a Madrid designation
• One Swiss registration also protects Liechtenstein by treaty

The trademark and the INN: naming a Basel drug brand

Basel is the world’s densest cluster of pharmaceutical head offices, and naming a drug here means reconciling two very different naming systems. Every new active substance receives an International Nonproprietary Name (INN) — a generic, public-domain name assigned by the World Health Organization so clinicians worldwide can identify the molecule. Citalopram, adalimumab and imatinib are INNs. The brand name is the trademark that sits on top of the molecule and travels with the finished product.

The two must never collide. WHO rules and health-authority practice forbid a trademark that is derived from an INN or that borrows an INN “stem” — the shared syllable (such as -mab for monoclonal antibodies or -tinib for kinase inhibitors) that signals a drug class. A proposed brand that echoes a stem risks refusal both as a trademark and at the regulatory stage, because it could mislead prescribers about what the product actually is.

For a Basel life-sciences company this shapes clearance from day one. A distinctive, invented brand — far enough from the INN and its stems, yet still available as a trademark across every target market — has to be engineered, not chosen casually. We screen candidate names against the trademark registers and against the INN and stem lists together, so a name that clears the IPI does not quietly fall over later at the regulator.

• The INN is the public-domain generic name; the trademark is the proprietary brand
• A trademark may not be derived from an INN or include an INN stem (e.g. -mab, -tinib)
• A name that copies a stem can be refused as a mark and at the regulatory stage
• Basel drug brands must be screened against trademark registers and INN stems together

Swissmedic clearance vs trademark registration: two separate hurdles

A trademark registration and a marketing authorisation are different approvals from different authorities, and a Basel pharma brand needs both. The IPI decides whether your name is registrable and distinctive as a trade mark. Swissmedic, the Swiss agency for therapeutic products, separately reviews the medicinal product name as part of authorising the drug for the Swiss market — and it applies its own, quite different test.

Under the Therapeutic Products Ordinance, Swissmedic will reject a medicinal product name that is misleading or liable to cause confusion with other products, or that could cause the composition, effect or safety of the medicine to be misunderstood. Its Medicinal Product Name guidance (HMV4) sets out this practice in detail. A name can therefore be a perfectly valid registered trademark yet still be refused by Swissmedic — and the reverse is equally possible.

The practical lesson for Basel brand owners is to run both checks in parallel, not in sequence. A name that clears the IPI but fails Swissmedic wastes the filing and the launch window; a name approved by Swissmedic but unregistrable as a mark leaves the brand unprotected against copyists. PerspireIP coordinates the trademark clearance and flags Swissmedic naming risks early, so the brand you file is the brand you can actually bring to market.

• Trademark registration (IPI) and drug-name approval (Swissmedic) are separate hurdles
• Swissmedic rejects names that mislead or risk confusion under the Therapeutic Products Ordinance
• A valid registered mark can still fail Swissmedic review, and the reverse is possible
• Run trademark clearance and Swissmedic naming checks in parallel, not one after the other

IPI fees, routes and the Madrid base for a Basel brand

The IPI keeps Swiss trade mark costs transparent. The basic filing fee is CHF 550 and covers up to three classes of goods and services, with CHF 100 for each additional class from the fourth onward — a real consideration for pharma and chemical portfolios that often span classes 1, 3, 5 and 10. Filing electronically through the IPI eTrademark portal earns a CHF 100 reduction. Protection runs ten years from the filing date and renews indefinitely in ten-year terms.

A Basel owner has two routes. The national route files directly at the IPI for a Swiss (and Liechtenstein) registration — fastest when Switzerland is the anchor market. The international route uses the Madrid Protocol, administered by WIPO in Geneva, to designate many countries from one application. Madrid still needs a home mark: the Swiss application or registration is the “basic mark” on which the international registration depends for its first five years.

For a Basel exporter the routes work together. A Madrid application can designate the European Union, which is how the brand reaches French and German consumers across the border — but that EU designation still never covers Switzerland, which must always be held as its own Swiss right. We usually file the Swiss national mark first and then build the Madrid strategy around the countries where the product will genuinely sell.

• Basic IPI fee CHF 550 for up to three classes; CHF 100 per class from the fourth
• CHF 100 discount for electronic filing via the IPI eTrademark portal
• Ten-year term, renewable indefinitely; national and Madrid routes work together
• The Swiss mark is the Madrid “basic mark”; a Madrid EU designation still never covers Switzerland

Filing across the Dreiländereck: one brand, three countries

Few European cities are as international at street level as Basel. The city sits at the Dreiländereck — the point on the Rhine where Switzerland, France and Germany meet — and Basel companies routinely sell, manufacture and recruit across all three borders. A brand launched here is, in commercial reality, a cross-border brand the moment it ships from the Rhine port.

That geography reshapes the filing plan. The Swiss mark (via the IPI) protects Switzerland and Liechtenstein; France and Germany are covered either by national filings, or far more efficiently by an EUTM or a Madrid designation of the European Union. A Basel brand owner therefore usually needs a Swiss right plus EU coverage running in tandem — neither one alone protects the whole trading area that a Basel company treats as its home region.

Origin claims matter here too. Basel’s pharma and chemical goods often trade on Swiss quality, and the “Swissness” rules that took effect on 1 January 2017 govern when a product may use the word “Swiss” or the Swiss cross — for industrial goods, at least 60% of the manufacturing cost must be incurred in Switzerland and the essential step must take place there. A distinctive brand that signals Swiss origin is only lawful in use if that reality is met, so the brand and the supply chain must line up before you file.

• Basel sits at the Dreiländereck where Switzerland, France and Germany meet
• Basel brands are cross-border from launch — Swiss cover alone is not enough
• Pair a Swiss mark (IPI) with EU cover (EUTM or a Madrid EU designation) for France and Germany
• “Swiss made” claims must meet the Swissness thresholds before a Swiss-origin brand is used

Where a Basel trademark dispute is actually heard

A widespread misconception is that Switzerland’s Federal Patent Court handles trade mark cases. It does not — the Federal Patent Court, seated in St. Gallen, has exclusive competence over patents only. Trade mark infringement, validity and ownership disputes are civil matters decided by the cantons, and here Basel differs sharply from Zurich.

Zurich, Berne, St. Gallen and Aargau each run a specialised commercial court. Basel-Stadt does not. Instead, the Appellationsgericht des Kantons Basel-Stadt sits as the sole cantonal instance for intellectual property disputes, deciding trademark matters at first and only instance regardless of the amount in dispute. For a Basel brand owner that means a single, specialised cantonal forum close to home rather than a separate commercial court in another canton.

The IPI, by contrast, runs the administrative side — examination, registration and the opposition procedure. An opposition against a newly published mark must be filed with the IPI within three months of publication, a short window that makes trade mark watching and prompt docketing essential. Contentious infringement and cancellation belong to the Appellationsgericht, and its decisions can be appealed only once, to the Swiss Federal Supreme Court in Lausanne on points of law.

• The Federal Patent Court in St. Gallen hears patents only — never trade marks
• Basel-Stadt has no commercial court; the Appellationsgericht is the sole cantonal IP instance
• It decides trademark disputes at first and only instance, regardless of the sum in dispute
• IPI oppositions run three months from publication; final appeals reach the Federal Supreme Court in Lausanne

How trademark filing Basel work unfolds with PerspireIP

Every trademark filing Basel engagement at PerspireIP follows a disciplined sequence, because for a pharma or chemical brand the cheapest protection comes from getting the strategy right before anything is submitted. We begin with a clearance search of the Swissreg register and the international records — and, for a drug brand, a parallel screen against the WHO INN and stem lists plus a read on Swissmedic naming risk — so you learn early whether a name is genuinely available and launchable.

From there we draft a precise specification against the Nice Classification, set a class strategy that balances coverage against cost across the pharma and chemical classes, and choose the route — a Swiss national filing at the IPI, a Madrid application, or both in sequence with an EU designation for the French and German markets. We file electronically to capture the eTrademark discount, answer any IPI examination objections, and monitor the three-month opposition window.

• Clearance search of Swissreg and international registers, plus INN-stem and Swissmedic naming screens
• Precise Nice-Classification specification and a cost-aware class strategy for pharma and chemical goods
• Route selection: Swiss national, Madrid Protocol, or a coordinated combination with an EU designation
• Electronic filing, IPI examination responses and opposition-window monitoring
• Renewal docketing and portfolio management for the full ten-year term and beyond

After registration we docket the renewal deadlines, watch for conflicting later marks across the Dreiländereck, and keep the portfolio aligned as the product expands into new countries. We work alongside your Swiss counsel where a dispute heads for the Appellationsgericht, and we keep every engagement confidential. Whether you are a biotech spin-off protecting a first molecule’s brand or an established Basel house extending a global portfolio, the goal is the same: a clean, enforceable Swiss right that holds where you actually trade.

IP Landscape & Resources in Basel

Key intellectual-property authorities and venues relevant to Basel:

• Swiss Federal Institute of Intellectual Property (IPI/IGE) — Switzerland's national IP office in Bern; examines and registers Swiss trade marks and maintains the Swissreg register
• WIPO Madrid System — administers the Madrid Protocol international registration used to extend a Swiss base mark to other countries
• Swissmedic — the Swiss agency for therapeutic products; reviews and can reject a misleading or confusable medicinal product name when authorising a drug
• Appellationsgericht des Kantons Basel-Stadt — sits as the sole cantonal instance for intellectual property and trademark disputes in Basel-Stadt

Request Trademark Filing in Basel

Explore related PerspireIP services: Trademark Filing · Trademark Search · our IP services.

Frequently Asked Questions